🇺🇸 FDA
Pipeline program

SD-809

SD-809-C-16

Phase 3 small_molecule completed

Quick answer

SD-809 for Chorea Associated With Huntington Disease is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Chorea Associated With Huntington Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials